Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO (MECROV)

Asociación para Evitar la Ceguera en México

Status and phase: Terminated; Phase 4

Conditions: Macular Edema; Central Retinal Vein Occlusion

Treatments: Drug: bevacizumab and triamcinolone

Study type: Interventional

Funder types: Other

Identifiers

NCT00566761

MECRVO

Details and patient eligibility

About

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Full description

Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Enrollment: 10 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Macular edema secondary to central retinal vein occlusion
• BCVA worse than 20/40
• Central macular >250 mc with OCT

Exclusion criteria

• Diabetic retinopathy or other retinopathy
• Media opacity that does not allow following
• steroid responder
• diagnosed glaucoma or IOP > 21 mmHg

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)